Before the rings, before the championships, before the MVPS, before the billions, before global stardom, Michael Jordan was ...
TipRanks on MSN
Neurocrine price target raised to $179 from $171 at JPMorgan
JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $179 from $171 and keeps an Overweight rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback